Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Denteric Pty Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. CHHAY, BONIRATH is the busiest examiner for this portfolio, with 1 pending office action.
This figure matches the total of 1 pending office action for the entire company, indicating that this examiner is responsible for all current pending prosecution. The focus on 1 distinct art unit suggests that the company's current legal efforts are centralized in one specific area of biotechnology and pharmaceutical review. Because the entire workload is managed by CHHAY, BONIRATH, the prosecution strategy is highly dependent on this single examiner's feedback. This concentration within the Biotechnology & Pharmaceuticals sector highlights a narrow but significant area of interest for the company's current patenting activities. The 1 distinct examiner is responsible for the 1 pending office action currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 66.7% | +44.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730629 | CHIMERIC POLYPEPTIDES | STEPHENS, AMELIA CAROLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18730629 | CHIMERIC POLYPEPTIDES | STEPHENS, AMELIA CAROLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18730629 | CHIMERIC POLYPEPTIDES | STEPHENS, AMELIA CAROLE | 1645 | §101§102§112Other | Non-Final OA | — | Pending | Jul 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDenteric Pty Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Amelia Carole Stephens has the most, with 1 of Denteric Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.